Drug reference

Clofarabine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 981

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Relapsed or refractory acute lymphoblastic leukaemia in patients who have received at least two previous regimens ▶BY INTRAVENOUS INFUSION ▶Adult 18–20 years: (consult local protocol)

PDF page 981

Cautions

Cardiac disease

PDF page 981

Safety

Interactions

→Appendix 1: clofarabine

PDF page 981

Side Effects

▶Common or very common Alopecia. anxiety. appetite decreased. arthralgia. capillary leak syndrome. chills. cough. dehydration. diarrhoea. dizziness. drowsiness. dyspnoea. fatigue. feeling abnormal. feeling hot. fever. ﬂushing. gastrointestinal discomfort. haemorrhage. headache. hearing impairment. hepatic disorders. hyperbilirubinaemia. hyperhidrosis. hypersensitivity. hypotension. increased risk of infection. irritability. mucositis. multi organ failure. myalgia. nausea. neutropenia. oedema. oral disorders. pain. paraesthesia. pericardial effusion. peripheral neuropathy. psychiatric disorder. renal impairment. respiratory disorders. sepsis. sinusoidal obstruction syndrome. skin reactions. systemic inﬂammatory response syndrome. tachycardia. tremor. tumour lysis syndrome. vomiting. weight decreased ▶Frequency not known Antibiotic associated colitis. gastrointestinal disorders. hyponatraemia. pancreatitis. severe cutaneous adverse reactions (SCARs)

PDF page 981

Conception And Contraception

Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 981

Pregnancy

Manufacturer advises avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 981

Breast Feeding

Discontinue breast-feeding.

PDF page 981

Hepatic Impairment

Manufacturer advises use with caution in mild-to-moderate impairment; avoid in severe impairment—no information available.

PDF page 981

Renal Impairment

Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.

PDF page 981

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for infusion ELECTROLYTES: May contain Sodium ▶Clofarabine (Non-proprietary) Clofarabine 1 mg per 1 ml Clofarabine 20mg/20ml concentrate for solution for infusion vials | 1 vial P £1,326.18 (Hospital only) ▶Evoltra (Sanofi) A Clofarabine 1 mg per 1 ml Evoltra 20mg/20ml concentrate for solution for infusion vials | 1 vial P £1,326.18 (Hospital only)

PDF page 981

Dose text by age group

Adult 18–20 years

(consult local protocol)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 981

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Clofarabine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 981

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Relapsed or refractory acute lymphoblastic leukaemia in patients who have received at least two previous regimens ▶BY INTRAVENOUS INFUSION ▶Adult 18–20 years: (consult local protocol)

PDF page 981

Cautions

Cardiac disease

PDF page 981

Safety

Interactions

→Appendix 1: clofarabine

PDF page 981

Side Effects

PDF page 981

Conception And Contraception

Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 981

Pregnancy

Manufacturer advises avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 981

Breast Feeding

Discontinue breast-feeding.

PDF page 981

Hepatic Impairment

Manufacturer advises use with caution in mild-to-moderate impairment; avoid in severe impairment—no information available.

PDF page 981

Renal Impairment

Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.

PDF page 981

Dose and formulations

Medicinal Forms

PDF page 981

Dose text by age group

Adult 18–20 years

(consult local protocol)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 981

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.